421P Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidines-based chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 35; p. S171
Main Authors Damato, A., Bilancia, D., Iachetta, F., Strippoli, A., Filiali, F., Casaretti, R., Bernardini, I., Bellotti, G., Frassineti, G.L., Di Fabio, F., Aieta, M., Ghidini, M., Trentin, C., Cardellino, G., Gervasi, E., Romagnani, A., Cinieri, S., Normanno, N., Boni, L., Pinto, C.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.06.2024
Online AccessGet full text

Cover

More Information
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2024.05.335